Loading
Surgeon-scientist who led IMpassion031 and studies of surgery de-escalation after neoadjuvant immunotherapy.
Elizabeth Mittendorf led IMpassion031, showing neoadjuvant atezolizumab plus chemotherapy raises pathological complete response in TNBC regardless of PD-L1 status, and ran the early HER2 peptide vaccine trials. As a breast surgeon she leads Alliance trials asking whether axillary surgery and radiotherapy can be omitted after excellent neoadjuvant response. She directs breast immuno-oncology at Dana-Farber.
Shares Atezolizumab, Triple-negative breast cancer (TNBC), Immune checkpoint inhibitors and the tags tnbc, immunotherapy.
Shares Cancer Immunology Research, Triple-negative breast cancer (TNBC).
Shares Dana-Farber Brigham Cancer Center, Immune checkpoint inhibitors and the tag immunotherapy.
Shares Cancer Immunology Research, Immune checkpoint inhibitors.
Shares Cancer Immunology Research, Immune checkpoint inhibitors.
Shares Dana-Farber Brigham Cancer Center, Immune checkpoint inhibitors and the tag immunotherapy.
Shares Sentinel lymph node biopsy, Triple-negative breast cancer (TNBC) and the tag surgery.
Shares Immune checkpoint inhibitors and the tags surgery, immunotherapy.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/